Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323140 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
A Phase 2 study of Hypogonadism, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT01323140 is a Phase 2 study of Hypogonadism that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 40 participants, below the 118-participant average among 21 other Hypogonadism trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01323140, a Phase 2 study of Hypogonadism, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
Conditions Studied
Interventions
- DRUG testosterone matrix transdermal system
Study Locations (2)
Florida
- Watson Investigational Site - Fort Meyers
Washington
- Watson Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323140
The ClinicalTrials.gov registry entry for NCT01323140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 21 other Hypogonadism trials with a reported enrollment target (66% lower). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which testosterone matrix transdermal system is the first listed.
NCT01323140 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT01323140 about?
NCT01323140 is a clinical study titled "Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems". Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
What is the current status of trial NCT01323140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-04. Estimated completion is 2011-07.
What conditions does trial NCT01323140 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT01323140?
The interventions under investigation include: testosterone matrix transdermal system (DRUG).
Who is sponsoring clinical trial NCT01323140?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01323140 being conducted?
This trial has 2 study locations across Florida, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
COMPLETED · Phase 2
-
Testosterone and Growth Hormone for Bone Loss in Men
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
COMPLETED · Phase 2
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.